Valeur ajoutée d'un bloquant de l'interleukine-1 à l'hypothermie thérapeutique dans le traitement des asphyxies néonatales

 

Mathilde Chevin

Institut de recherche du Centre universitaire de santé McGill

 

Domaine : santé de la mère, des enfants et des adolescents

Programme Formation de doctorat

Concours 2018-2019

Partenaire :

Brain Canada

Neonatal asphyxia (decrease in oxygen and blood supplies to the brain) is a severe pathology generating major brain injuries such as cerebral palsy. Therapeutic hypothermia (decreased body temperature to 33-34°C during 3 days) is the only treatment available for these newborns. Despite hypothermia treatment, more than 50% of these newborns present neurological sequelae. This highlights the need to look for new neuroprotective treatments.

Our laboratory tests the efficacy of an anti-inflammatory molecule (IL-1Ra) combined with hypothermia to prevent neonatal cerebral injuries. Our results will uncover the inflammatory mechanisms leading to neuronal death following neonatal asphyxia. This will open new therapeutic avenues to prevent cerebral palsy.